HeadaTerm 2: An Affordable FDA-Cleared Alternative to Cefaly for Migraine Relief
Posted on April 29 2024,
If you have migraine disease, you may have heard of Cefaly - the popular FDA-approved device that uses external trigeminal nerve stimulation (eTNS) technology to prevent and treat migraine headaches. While effective, Cefaly comes with a hefty price tag of around $350. But there's good news for patients with migraine on a budget. A newer device called HeadaTerm 2 utilizes the same eTNS technology as Cefaly at a much more affordable price point of just $99.99. In fact, HeadaTerm 2 is currently offering a pre-sale discount of up to 30% off, bringing the cost down to $70.
How does HeadaTerm 2 work?
Like Cefaly, HeadaTerm 2 is worn on the forehead and delivers targeted electrical impulses to stimulate the trigeminal nerve, which has been shown to increase pain tolerance and prevent migraine attacks. In clinical trials, eTNS was found to be up to 27% more effective than oral migraine medications - without the unwanted side effects.
Acute Treatment: Use medium to high intensity for continuous treatment of one hour. If the migraine attack is not fully relieved, add an additional hour.
Preventive Treatment: Use low to medium intensity for continuous treatment of one hour daily. First-time users of e-TNS technology products may experience mild discomfort due to electrical stimulation. It is recommended to start at a low intensity for the first 1-2 sessions (adaptive treatment).
Key features of HeadaTerm 2
- FDA clearance for safety and effectiveness in migraine prevention
- No need for a prescription
- Rechargeable for repeated use
- Simple one-button control to adjust stimulation intensity
- Compact, portable design for on-the-go treatment
- 100% drug-free
- Quick migraine relief
- Affordably priced under $100
HeadaTerm 2 offers a very compelling alternative for those looking for a more budget-friendly option. With its clinically proven effectiveness, ease of use, and reasonable cost, HeadaTerm 2 is well worth considering if you're seeking a non-invasive, drug-free way to prevent and relieve migraine headaches.
When the pre-sale is gone, you can use our code CEREBRALTORQUE for a 20% discount.
Get HeadaTerm 2 NowThu, Apr 24, 25
Clinical Predictors for Efficacy of Erenumab (Aimovig) for Migraine
Discover key predictors of Aimovig (erenumab) response in migraine patients. This REFORM study reveals which patients benefit most from CGRP therapy and why timing matters. Evidence-based insights for better treatment...
Read MoreWed, Apr 23, 25
Effectiveness and Tolerability of Atogepant (Qulipta) in the Prevention of Migraine
STAR study shows atogepant (Qulipta) effectively reduces migraine days by 56.6% in real-world clinical practice, even for patients with previous treatment failures. Learn about this breakthrough.
Read MoreWed, Apr 23, 25
Impact of Visual Stimulus Complexity on Associative Learning in Migraine Patients
Groundbreaking research reveals how migraine patients process visual information differently. This 2025 study found that migraine patients take longer to process simple visual stimuli compared to complex images, which is...
Read More